Mariner LLC Buys 17,800 Shares of Astrazeneca Plc $AZN

Mariner LLC lifted its holdings in Astrazeneca Plc (NYSE:AZN) by 2.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 690,319 shares of the company’s stock after purchasing an additional 17,800 shares during the quarter. Mariner LLC’s holdings in Astrazeneca were worth $121,151,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently modified their holdings of the company. Lloyd Advisory Services LLC. purchased a new stake in Astrazeneca during the fourth quarter valued at $35,000. Basepoint Wealth LLC bought a new stake in Astrazeneca during the fourth quarter valued at about $44,000. Acumen Wealth Advisors LLC bought a new stake in Astrazeneca during the fourth quarter valued at about $47,000. Nemes Rush Group LLC grew its holdings in Astrazeneca by 162.1% during the fourth quarter. Nemes Rush Group LLC now owns 270 shares of the company’s stock valued at $47,000 after purchasing an additional 167 shares during the period. Finally, Bangor Savings Bank boosted its stake in shares of Astrazeneca by 102.7% in the fourth quarter. Bangor Savings Bank now owns 304 shares of the company’s stock worth $28,000 after acquiring an additional 154 shares during the period. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Astrazeneca Stock Down 0.8%

Shares of NYSE AZN opened at $177.36 on Tuesday. The company has a current ratio of 0.91, a quick ratio of 0.71 and a debt-to-equity ratio of 0.52. The stock has a market capitalization of $275.07 billion, a PE ratio of 26.63, a price-to-earnings-growth ratio of 1.55 and a beta of 0.25. The stock’s fifty day simple moving average is $188.74 and its two-hundred day simple moving average is $186.10. Astrazeneca Plc has a 12-month low of $137.23 and a 12-month high of $212.71.

Astrazeneca (NYSE:AZN) last announced its earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.52 by $0.06. The business had revenue of $15.29 billion for the quarter, compared to analysts’ expectations of $14.93 billion. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%. As a group, analysts expect that Astrazeneca Plc will post 9.39 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of Astrazeneca in a research note on Tuesday, June 9th. Weiss Ratings restated a “buy (b)” rating on shares of Astrazeneca in a research report on Monday, June 8th. JPMorgan Chase & Co. restated a “buy” rating on shares of Astrazeneca in a research report on Tuesday, June 9th. Morgan Stanley restated an “overweight” rating on shares of Astrazeneca in a research report on Wednesday, April 8th. Finally, Wall Street Zen upgraded Astrazeneca from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Twelve analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $205.33.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.